Nurix Therapeutics presented new clinical data on NX-1607, showing evidence of monotherapy anti-tumor activity and on-target immune activation. Expansion cohorts at higher doses are planned for advanced solid tumors. The drug targets CBL-B and demonstrated dose-dependent exposure, immune activation, and reductions in tumor volume. NX-1607 has a safety profile comparable to approved immuno-oncology agents, with most adverse events being mild. Promising clinical activity was observed in patients with advanced disease, including reductions in tumor-specific biomarkers and stable disease. The drug is being further evaluated in an ongoing Phase 1 trial.

Read more at GlobeNewswire: Nurix Therapeutics Reports New Clinical Data from